Skip to main content

Xhance Disease Interactions

There are 5 disease interactions with Xhance (fluticasone nasal).

Moderate

Inhaled corticosteroids (applies to Xhance) infections

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Infection - Bacterial/Fungal/Protozoal/Viral, Tuberculosis -- Latent

The immunosuppressant and anti-inflammatory effects of corticosteroids, particularly in higher dosages, may decrease host resistance to infectious agents, decrease the ability to localize infections, and mask the symptoms of infection. Secondary infections may be more likely to develop. Therapy with corticosteroids should be administered cautiously in patients with an infection, particularly active or quiescent tuberculosis or in hepatitis B carriers. Monitor patients for any new or worsening infection and use with caution in these patients. A serious or even fatal course of chickenpox and measles can occur in susceptible patients. It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.

References (18)
  1. (2001) "Product Information. Beclovent (beclomethasone)." Glaxo Wellcome
  2. (2001) "Product Information. Vancenase (beclomethasone)." Glaxo Wellcome
  3. (2022) "Product Information. AeroBid (flunisolide)." Forest Pharmaceuticals
  4. (2001) "Product Information. Nasalide (flunisolide)." Syntex Laboratories Inc
  5. (2001) "Product Information. Flonase (fluticasone)." Glaxo Wellcome
  6. (2001) "Product Information. Rhinocort (budesonide)." Astra-Zeneca Pharmaceuticals
  7. (2001) "Product Information. Flovent (fluticasone)." Glaxo Wellcome
  8. "Product Information. Nasonex (mometasone nasal)." Scherer Laboratories Inc
  9. (2001) "Product Information. Pulmicort Turbuhaler (budesonide)." Astra-Zeneca Pharmaceuticals
  10. (2001) "Product Information. Azmacort (triamcinolone)." Rhone Poulenc Rorer
  11. (2001) "Product Information. Nasacort (triamcinolone nasal)." Rhone Poulenc Rorer
  12. (2001) "Product Information. Pulmicort Respules (budesonide)." Astra-Zeneca Pharmaceuticals
  13. (2008) "Product Information. Alvesco (ciclesonide)." Nycomed USA
  14. (2008) "Product Information. Omnaris (ciclesonide nasal)." Sepracor Inc
  15. (2013) "Product Information. Uceris (budesonide)." Santarus Inc
  16. (2016) "Product Information. Pulmicort Flexhaler (budesonide)." A-S Medication Solutions
  17. (2016) "Product Information. Entocort EC (budesonide)." Perrigo, L. Company
  18. (2024) "Product Information. Eohilia (budesonide)." Takeda Pharmaceuticals America

Switch to consumer interaction data

Moderate

Inhaled corticosteroids (applies to Xhance) ocular herpes simplex

Moderate Potential Hazard, Moderate plausibility.

Pharmacologic dosages of corticosteroids may increase the risk of corneal perforation in patients with ocular herpes simplex. Therapy with inhaled and nasal corticosteroids should be administered cautiously in such patients.

References (13)
  1. (2001) "Product Information. Beclovent (beclomethasone)." Glaxo Wellcome
  2. (2001) "Product Information. Vancenase (beclomethasone)." Glaxo Wellcome
  3. (2022) "Product Information. AeroBid (flunisolide)." Forest Pharmaceuticals
  4. (2001) "Product Information. Nasalide (flunisolide)." Syntex Laboratories Inc
  5. (2001) "Product Information. Flonase (fluticasone)." Glaxo Wellcome
  6. (2001) "Product Information. Rhinocort (budesonide)." Astra-Zeneca Pharmaceuticals
  7. (2001) "Product Information. Flovent (fluticasone)." Glaxo Wellcome
  8. "Product Information. Nasonex (mometasone nasal)." Scherer Laboratories Inc
  9. (2001) "Product Information. Pulmicort Turbuhaler (budesonide)." Astra-Zeneca Pharmaceuticals
  10. (2001) "Product Information. Azmacort (triamcinolone)." Rhone Poulenc Rorer
  11. (2001) "Product Information. Nasacort (triamcinolone nasal)." Rhone Poulenc Rorer
  12. (2008) "Product Information. Alvesco (ciclesonide)." Nycomed USA
  13. (2008) "Product Information. Omnaris (ciclesonide nasal)." Sepracor Inc

Switch to consumer interaction data

Moderate

Inhaled corticosteroids (applies to Xhance) ocular toxicities

Moderate Potential Hazard, Low plausibility. Applicable conditions: Glaucoma/Intraocular Hypertension, Cataracts

Prolonged use of corticosteroids may cause posterior subcapsular cataracts and elevated intraocular pressure, the latter of which may lead to glaucoma and/or damage to the optic nerves. Therapy with corticosteroids should be administered cautiously nonetheless in patients with a history of cataracts, glaucoma, or increased intraocular pressure. Although adverse effects of corticosteroids may be minimized by local rather than systemic administration, the risks are not entirely abolished. Inhaled and nasally applied drug may be absorbed into the circulation, especially when large doses are used. It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.

References (18)
  1. (2001) "Product Information. Beclovent (beclomethasone)." Glaxo Wellcome
  2. (2001) "Product Information. Vancenase (beclomethasone)." Glaxo Wellcome
  3. (2022) "Product Information. AeroBid (flunisolide)." Forest Pharmaceuticals
  4. (2001) "Product Information. Nasalide (flunisolide)." Syntex Laboratories Inc
  5. (2001) "Product Information. Flonase (fluticasone)." Glaxo Wellcome
  6. (2001) "Product Information. Rhinocort (budesonide)." Astra-Zeneca Pharmaceuticals
  7. (2001) "Product Information. Flovent (fluticasone)." Glaxo Wellcome
  8. "Product Information. Nasonex (mometasone nasal)." Scherer Laboratories Inc
  9. (2001) "Product Information. Pulmicort Turbuhaler (budesonide)." Astra-Zeneca Pharmaceuticals
  10. (2001) "Product Information. Azmacort (triamcinolone)." Rhone Poulenc Rorer
  11. (2001) "Product Information. Nasacort (triamcinolone nasal)." Rhone Poulenc Rorer
  12. (2001) "Product Information. Pulmicort Respules (budesonide)." Astra-Zeneca Pharmaceuticals
  13. (2008) "Product Information. Alvesco (ciclesonide)." Nycomed USA
  14. (2008) "Product Information. Omnaris (ciclesonide nasal)." Sepracor Inc
  15. (2013) "Product Information. Uceris (budesonide)." Santarus Inc
  16. (2016) "Product Information. Pulmicort Flexhaler (budesonide)." A-S Medication Solutions
  17. (2016) "Product Information. Entocort EC (budesonide)." Perrigo, L. Company
  18. (2024) "Product Information. Eohilia (budesonide)." Takeda Pharmaceuticals America

Switch to consumer interaction data

Moderate

Inhaled corticosteroids (applies to Xhance) osteoporosis

Moderate Potential Hazard, Moderate plausibility.

Prolonged use of inhaled corticosteroids may be associated with a reduction in bone density. This effect appears to be dose-related and has been reported primarily with high dosages (800 mcg/day or more of beclomethasone or equivalent for 1 year or greater). Reduced levels of total body calcium have also been demonstrated in patients receiving lower dosages. Long-term therapy with inhaled and nasal corticosteroids should be administered cautiously in patients with osteoporosis. It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.

References (24)
  1. Grahnen A, Eckernas SA, Brundin RM, Lingandersson A (1994) "An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers." Br J Clin Pharmacol, 38, p. 521-5
  2. Toogood JH, Crilly RG, Jones G, Nadeau J, Wells GA (1988) "Effect of high-dose inhaled budesonide on calcium and phosphate metabolism and the risk of osteoporosis." Am Rev Respir Dis, 138, p. 57-61
  3. Edsbacker S, Andersson KE, Ryrfeldt A (1985) "Nasal bioavailability and systemic effects of the glucocorticoid budesonide in man." Eur J Clin Pharmacol, 29, p. 477-81
  4. Konig P, Hillman L, Cervantes C, Levine C, Maloney C, Douglass B, Johnson L, Allen S (1993) "Bone metabolism in children with asthma treated with inhaled beclomethasone dipropionate." J Pediatr, 122, p. 219-26
  5. Kinberg KA, Hopp RJ, Biven RE, Gallagher JC (1994) "Bone mineral density in normal and asthmatic children." J Allergy Clin Immunol, 94, p. 490-7
  6. Barnes PJ (1995) "Drug therapy: inhaled glucocorticoids for asthma." N Engl J Med, 332, p. 868-75
  7. Toogood JH, Baskerville JC, Markov AE, Hodsman AB, Fraher LJ, Jennings B, Haddad RG, Drost D (1995) "Bone mineral density and the risk of fracture in patients receiving long-term inhaled steroid therapy for asthma." J Allergy Clin Immunol, 96, p. 157-66
  8. Hanania NA, Chapman KR, Sturtridge WC, Szalai JP, Kesten S (1995) "Dose-related decrease in bone density among asthmatic patients treated with inhaled corticosteroids." J Allergy Clin Immunol, 96, p. 571-9
  9. Martinati LC, Bertoldo F, Gasperi E, Micelli S, Boner AL (1996) "Effect on cortical and trabecular bone mass of different anti-inflammatory treatments in preadolescent children with chronic asthma." Am J Respir Crit Care Med, 153, p. 232-6
  10. Packe GE, Douglas JG, McDonald AF, Robins SP, Reid DM (1992) "Bone density in asthmatic patients taking high dose inhaled beclomethasone diproprionate and intermittent systemic corticosteroids." Thorax, 47, p. 414-7
  11. Reid DM, Nicoll JJ, Smith MA, Higgins B, Tothill P, Nuki G (1986) "Corticosteroids and bone mass in asthma: comparisons with rheumatoid arthritis and polymyalgia rheumatica." BMJ, 293, p. 1463-6
  12. Ali NJ, Capewell S, Ward MJ (1991) "Bone turnover during high dose inhaled corticosteroid treatment." Thorax, 46, p. 160-4
  13. Howland WC (1996) "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy, 26 ( Suppl, p. 18-22
  14. Packe GE, Robb O, Robins SP, Reid DM, Douglas JG (1996) "Bone density in asthmatic patients taking inhaled corticosteroids: comparison of budesonide and beclomethasone dipropionate." J R Coll Physicians Lond, 30, p. 128-32
  15. Thorsson L, Dahlstrom K, Edsbacker S, Kallen A, Paulson J, Wiren JE (1997) "Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects." Br J Clin Pharmacol, 43, p. 155-61
  16. McEvoy CE, Niewoehner DE (1997) "Adverse effects of corticosteroid therapy for COPD - A critical review." Chest, 111, p. 732-43
  17. Wiseman LR, Benfield P (1997) "Intranasal fluticasone propionate: A reappraisal of its pharmacology and clinical efficacy in the treatment of rhinitis." Drugs, 53, p. 885-907
  18. Luengo M, delRio L, Pons F, Picado C (1997) "Bone mineral density in asthmatic patients treated with inhaled corticosteroids: a case-control study." Eur Respir J, 10, p. 2110-3
  19. Wisniewski AF, Lewis SA, Green DJ, Maslanka W, Burrell H, Tattersfield AE (1997) "Cross sectional investigation of the effects of inhaled corticosteroids on bone density and bone metabolism in patients with asthma." Thorax, 52, p. 853-60
  20. Derom E, Schoor JV, Verhaeghe W, Vincken W, Pauwels R (1999) "Systemic effects of inhaled fluticasone propionate and budesonide in adult patients with asthma." Am J Respir Crit Care Med, 160, p. 157-61
  21. Wong CA, Walsh LJ, Smith CJP, Wisniewski AF, Lewis SA, Hubbard R, Cawte S, Green DJ, Pringle M, Tattersfield AE (2000) "Inhaled corticosteroid use and bone-mineral density in patients with asthma." Lancet, 355, p. 1399-403
  22. Israel E, Banerjee TR, Fitzmaurice GM, Kotlov TV, LaHive K, LeBoff MS (2001) "Effects of inhaled glucocorticoids on bone density in premenopausal women." N Engl J Med, 345, p. 941-7
  23. Sharma PK, Malhotra S, Pandhi P, Kumar N (2003) "Effect of inhaled steroids on bone mineral density: a meta-analysis." J Clin Pharmacol, 43, p. 193-7
  24. Boulet LP, Milot J, Gagnon L, Poubelle PE, Brown J (1999) "Long-term influence of inhaled corticosteroids on bone metabolism and density. Are biological markers predictors of bone loss?" Am J Respir Crit Care Med, 159, p. 838-44

Switch to consumer interaction data

Moderate

Inhaled/nasal corticosteroids (applies to Xhance) hyperadrenocorticism

Moderate Potential Hazard, Moderate plausibility.

The use of corticosteroids may rarely precipitate or aggravate conditions of hyperadrenocorticism. Although adverse effects of corticosteroids may be minimized by local rather than systemic administration, the risks are not entirely abolished. Inhaled and nasally applied drug may be absorbed into the circulation, especially when large doses are used. It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used. The development of symptoms such as menstrual irregularities, acneiform lesions, cataracts and cushingoid features during inhaled or nasal corticosteroid therapy may indicate excessive use.

References (18)
  1. (2001) "Product Information. Beclovent (beclomethasone)." Glaxo Wellcome
  2. (2001) "Product Information. Vancenase (beclomethasone)." Glaxo Wellcome
  3. (2022) "Product Information. AeroBid (flunisolide)." Forest Pharmaceuticals
  4. (2001) "Product Information. Nasalide (flunisolide)." Syntex Laboratories Inc
  5. (2001) "Product Information. Flonase (fluticasone)." Glaxo Wellcome
  6. (2001) "Product Information. Rhinocort (budesonide)." Astra-Zeneca Pharmaceuticals
  7. (2001) "Product Information. Flovent (fluticasone)." Glaxo Wellcome
  8. "Product Information. Nasonex (mometasone nasal)." Scherer Laboratories Inc
  9. (2001) "Product Information. Pulmicort Turbuhaler (budesonide)." Astra-Zeneca Pharmaceuticals
  10. (2001) "Product Information. Azmacort (triamcinolone)." Rhone Poulenc Rorer
  11. (2001) "Product Information. Nasacort (triamcinolone nasal)." Rhone Poulenc Rorer
  12. (2001) "Product Information. Pulmicort Respules (budesonide)." Astra-Zeneca Pharmaceuticals
  13. (2008) "Product Information. Alvesco (ciclesonide)." Nycomed USA
  14. (2008) "Product Information. Omnaris (ciclesonide nasal)." Sepracor Inc
  15. (2013) "Product Information. Uceris (budesonide)." Santarus Inc
  16. (2016) "Product Information. Pulmicort Flexhaler (budesonide)." A-S Medication Solutions
  17. (2016) "Product Information. Entocort EC (budesonide)." Perrigo, L. Company
  18. (2024) "Product Information. Eohilia (budesonide)." Takeda Pharmaceuticals America

Switch to consumer interaction data

Xhance drug interactions

There are 51 drug interactions with Xhance (fluticasone nasal).

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer